PR Newswire | Jun 10, 2021 07:00PM EDT

Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against FibroGen, Inc. - FGEN

06/10 18:00 CDT

FIBROGEN 24 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against FibroGen, Inc. - FGEN NEW ORLEANS, June 10, 2021

NEW ORLEANS, June 10, 2021 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until June 11, 2021 to file lead plaintiff applications in securities class action lawsuits against FibroGen, Inc. (NasdaqGS: FGEN), if they purchased the Company's securities and/or sold put options between October 18, 2017 and April 6, 2021, inclusive (the "Class Period"). These actions are pending in the United States District Court for the Northern District of California.

What You May DoIf you purchased securities and/or sold put options of FibroGen and would like to discuss your legal rights and how these cases might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqgs-fgen/ to learn more. If you wish to serve as a lead plaintiff in the class actions, you must petition the Courts by June 11, 2021.

About the LawsuitsFibroGen and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. On April 6, 2021, post-market, the Company disclosed that cardiovascular safety data it had previously submitted for the Phase 3 program of its roxadustat product "included post-hoc changes to the stratification factors." As a result of these changes, the complaint alleges, the Company was forced to concede that roxadustat did not reduce the risk of cardiovascular events or hospitalization as compared to a currently approved anemia injection used as a control based on pre-specified stratification factors, contrary to prior representations. On this news, shares of FibroGen plummeted $14.90, or 43%, to close at $19.74 per share on April 7, 2021, on heavy volume.

The first-filed case is Xu v. Fibrogen, Inc., et al.,No. 21-cv- 2623.

About Kahn Swick & Foti, LLCKSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. KSF serves a variety of clients - including public institutional investors, hedge funds, money managers and retail investors - in seeking to recover investment losses due to corporate fraud and malfeasance by publicly traded companies. KSF has offices in New York, California and Louisiana.

To learn more about KSF, you may visit www.ksfcounsel.com.

Contact:Kahn Swick & Foti, LLCLewis Kahn, Managing Partnerlewis.kahn@ksfcounsel.com1-877-515-18501100 Poydras St., Suite 3200New Orleans, LA 70163

View original content to download multimedia: http://www.prnewswire.com/news-releases/fibrogen-24-hour-deadline-alert-former-louisiana-attorney-general-and-kahn-swick--foti-llc-remind-investors-with-losses-in-excess-of-100-000-of-deadline-in-class-action-lawsuits-against-fibrogen-inc--fgen-301310543.html

SOURCE Kahn Swick & Foti, LLC